LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Elenco Azioni・Sana Biotechnology Inc

Sana Biotechnology Inc

Chiusa

SettoreSettore sanitario

2.67 -10.1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.66

Massimo

2.9

Metriche Chiave
By Trading Economics
Entrata	12M -47M
EPS	-0.171
Dipendenti	142
EBITDA	23M -35M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+231.08% upside

Dividendi
By Dow Jones
Utili prossimi	7 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-68M 893M
Apertura precedente	12.77
Chiusura precedente	2.67

Notizie sul Sentiment di mercato

By Acuity

25%

75%

64 / 344 Classifica in Healthcare

Sana Biotechnology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 giu 2026, 19:20 UTC

I principali Market Mover

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 giu 2026, 21:27 UTC

Utili

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 giu 2026, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Hog Futures Tumble to Close Week -- Market Talk

5 giu 2026, 19:10 UTC

Discorsi di Mercato

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 giu 2026, 19:03 UTC

Discorsi di Mercato

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 giu 2026, 18:59 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 giu 2026, 18:47 UTC

Discorsi di Mercato

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 giu 2026, 18:34 UTC

Discorsi di Mercato

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 giu 2026, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 giu 2026, 17:50 UTC

Utili

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 giu 2026, 17:27 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 giu 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

5 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 15:26 UTC

Discorsi di Mercato

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 giu 2026, 15:25 UTC

Utili

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Zcash Tumbles After Exploit Found -- Market Talk

5 giu 2026, 15:09 UTC

Discorsi di Mercato

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 giu 2026, 15:07 UTC

Discorsi di Mercato

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 giu 2026, 15:05 UTC

Discorsi di Mercato

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Confronto tra pari

Modifica del prezzo

Sana Biotechnology Inc Previsione

Obiettivo di Prezzo

By TipRanks

231.08% in crescita

Previsioni per 12 mesi

Media 9.8 USD 231.08%

Alto 16 USD

Basso 7 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sana Biotechnology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Sana Biotechnology Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

64 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.